Medtronic makes insulin suspending device available

Medtronic – which researches and produces diabetes solutions – has announced the availability of its Medtronic Paradigm Veo product in over 50 countries.

The technology is designed to provide protection against the risks associated with hypoglycemia and can suspend the delivery of insulin when it detects that glucose levels have fallen below a patients’ recommended threshold.

This could help to tackle the onset of hypoglycemia, which can cause diabetes sufferers to experience a seizure, slip into a coma or die.

Chris O’Connell, president of the diabetes business and senior vice-president at Medtronic, stated: “While not a cure for diabetes, we believe this automatic feature offers added protection, greater confidence and may lower the risk of injury associated with hypoglycemic events.”

In other Medtronic news, the firm announced in July that its Melody Transcatheter Pulmonary Valve was given unanimous backing by the Circulatory System Devices Panel.